Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 3/20 | 0.46 |
| ▸ | ADA | P00813 | 1/20 | 0.37 |
| ▸ | POLRMT | O00411 | 1/20 | 0.36 |
| ▸ | PRMT5 | O14744 | 4/20 | 0.34 |
| ▸ | WDR77 | Q9BQA1 | 4/20 | 0.34 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.33 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.33 |
| ▸ | PI4KA | P42356 | 1/20 | 0.33 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.33 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.33 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.33 |
| ▸ | TMPRSS2 | O15393 | 1/20 | 0.33 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.32 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.32 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19644967 | 1.00 | ADORA2A (0.46) | ADORA2AADAPOLRMTPRMT5WDR77 | |
| SCHEMBL17117149 | 1.00 | ADORA2A (0.46) | ADORA2AADAPOLRMTPRMT5WDR77 | |
| SCHEMBL17109576 | 1.00 | ADORA2A (0.46) | ADORA2AADAPOLRMTPRMT5WDR77 | |
| SCHEMBL2722884 | 1.00 | ADORA2A (0.46) | ADORA2AADAPOLRMTPRMT5WDR77 | |
| SCHEMBL13519758 | 1.00 | ADORA2A (0.46) | ADORA2AADAPOLRMTPRMT5WDR77 | |
| SCHEMBL13695331 | 1.00 | ADORA2A (0.46) | ADORA2AADAPOLRMTPRMT5WDR77 | |
| SCHEMBL31228150 | 0.90 | ADORA2A (0.36) | ADORA2APOLRMTPRMT5WDR77DOT1L | |
| SCHEMBL15682916 | 0.89 | ADORA2A (0.39) | ADORA2APOLRMTADORA3DOT1LPI4KA | |
| SCHEMBL17615387 | 0.87 | ADORA2A (0.38) | ADORA2APOLRMTADORA3DOT1LPI4KA | |
| SCHEMBL18697877 | 0.87 | ADORA2A (0.38) | ADORA2APOLRMTADORA3DOT1LPI4KA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8501699-B2 | Bicyclic nucleosides and nucleotides as therapeutic agents | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2013-08-06 | — | — | US | claimed |
| US-8415309-B2 | Bicyclic nucleosides and nucleotides as therapeutic agents | BIOTA SCIENTIFIC MANAGMENT PTY LTD (AT) | 2013-04-09 | — | — | US | claimed |
| US-20130018013-A1 | BICYCLIC NUCLEOSIDES AND NUCLEOTIDES AS THERAPEUTIC AGENTS | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2013-01-17 | — | — | US | claimed |
| US-20120122811-A1 | BICYCLIC NUCLEOSIDES AND NUCLEOTIDES AS THERAPEUTIC AGENTS | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2012-05-17 | — | — | US | claimed |
| US-8119607-B2 | Bicyclic nucleosides and nucleotides as therapeutic agents | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2012-02-21 | — | — | US | claimed |
| US-20100035836-A1 | BICYCLIC NUCLEOSIDES AND NUCLEOTIDES AS THERAPEUTIC AGENTS | BIOTA SCIENTIFIC MANAGEMENT (AU) | 2010-02-11 | — | — | US | claimed |
| US-12595506-B2 | Compositions and methods for analyzing modified nucleotides | NEW ENGLAND BIOLABS, INC. (US) | 2026-04-07 | — | — | US | disclosed |
| EP-4705313-A2 | 4'-SUBSTITUTED NUCLEOSIDES AND NUCLEOTIDES AS ANTIVIRAL AGENTS | The Scripps Research Institute (US) | 2026-03-11 | — | — | EP | disclosed |
| US-20250213601-A1 | METHODS AND BIOAVAILABLE HIGHLY PERMEABLE COMPOUNDS FOR THE TREATMENT OF VIRAL DISEASES | Didenko, Kirill (US) | 2025-07-03 | — | — | US | disclosed |
| WO-2024227159-A2 | 4'-SUBSTITUTED NUCLEOSIDES AND NUCLEOTIDES AS ANTIVIRAL AGENTS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2024-10-31 | — | — | WO | disclosed |
| US-20240271189-A1 | Compositions and Methods for Analyzing Modified Nucleotides | NEW ENGLAND BIOLABS, INC. (US) | 2024-08-15 | — | — | US | disclosed |
| US-11939628-B2 | Compositions and methods for analyzing modified nucleotides | NEW ENGLAND BIOLABS, INC. (US) | 2024-03-26 | — | — | US | disclosed |
| WO-2023187599-A1 | METHODS AND BIOAVAILABLE HIGHLY PERMEABLE COMPOUNDS FOR THE TREATMENT OF VIRAL DISEASES | DIDENKO KIRILL (MX) | 2023-10-05 | — | — | WO | disclosed |
| US-20100015094-A1 | ANTIVIRAL NUCLEOSIDE ANALOGS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2010-01-21 | — | — | US | disclosed |
| US-20100015094-A1 | ANTIVIRAL NUCLEOSIDE ANALOGS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2010-01-21 | — | — | US | disclosed |
| WO-2010002877-A2 | BYCYCLIC NUCLEOSIDES AND NUCLEOTIDES AS THERAPEUTIC AGENTS | BIOTA SCIENTIFIC MANAGEMENT (AU) | 2010-01-07 | — | — | WO | disclosed |
| WO-2010002877-A2 | BYCYCLIC NUCLEOSIDES AND NUCLEOTIDES AS THERAPEUTIC AGENTS | BIOTA SCIENTIFIC MANAGEMENT (AU) | 2010-01-07 | — | — | WO | disclosed |
| WO-2009111653-A2 | ANTIVIRAL THERAPEUTIC AGENTS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2009-09-11 | — | — | WO | disclosed |
| WO-2008141079-A1 | TETRAHYDROFURO [3 4-D] DIOXOLANE COMPOUNDS FOR USE IN THE TREATMENT OF VIRAL INFECTIONS AND CANCER | BIOCRYST PHARMACEUTICALS, INC. (US) | 2008-11-20 | — | — | WO | disclosed |
| WO-2008089105-A2 | ANTIVIRAL NUCLEOSIDE ANALOGS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2008-07-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122811-A1 | BICYCLIC NUCLEOSIDES AND NUCLEOTIDES AS THERAPEUTIC AGENTS | NTPCR, PNP, DCTD | ADORA2A 69/4885ADA 34/4885POLRMT 54/4885 |
| US-20100015094-A1 | ANTIVIRAL NUCLEOSIDE ANALOGS | TYMP, SAMHD1, TYMS | ADORA2A 795/4885ADA 72/4885POLRMT 62/4885 |
| US-20100035836-A1 | BICYCLIC NUCLEOSIDES AND NUCLEOTIDES AS THERAPEUTIC AGENTS | NTPCR, PNP, DCTD | ADORA2A 69/4885ADA 34/4885POLRMT 54/4885 |
| US-20250213601-A1 | METHODS AND BIOAVAILABLE HIGHLY PERMEABLE COMPOUNDS FOR THE TREATMENT OF VIRAL DISEASES | ACE2, FURIN, SARS1 | ADORA2A 2769/4885ADA 942/4885POLRMT 802/4885 |
| US-20130018013-A1 | BICYCLIC NUCLEOSIDES AND NUCLEOTIDES AS THERAPEUTIC AGENTS | NTPCR, PNP, DCTD | ADORA2A 69/4885ADA 34/4885POLRMT 54/4885 |
| US-12595506-B2 | Compositions and methods for analyzing modified nucleotides | UNG, RNMT, NT5C3B | ADORA2A 789/4885ADA 15/4885POLRMT 67/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.